A greater percentage of the patients with PIK3CA amplifications had diffuse-type gastric cancer (52.9% vs. 38.7%, P=0.004) and poorly differentiated adenocarcinoma (60.7% vs. 48.4%, P=0.031) compared with those patients without PIK3CA amplifications. The gene discussed is PIK3CA; the disease is adenocarcinoma.